Cost‐effectiveness of chemotherapy for sputum smear‐positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania

Jonghe, E. De; Murray, Christopher J L; Chum, H. J.; Nyangulu, D.S.; Salomao, A.; Stýblo, K

doi:10.1002/hpm.4740090204

Cited by 19 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98 Shortcourse chemotherapy was preferable to standard 12-month chemotherapy, and the costeffectiveness ratios were remarkably similar across locations despite differences in the costs of food and labour. The authors commented that generalising the results to other developing countries may be questionable, however, because of differences in national incomes per capita where the cost of labour might be much higher in dollar terms.…”

Section: Empirical Analyses Of Geographical Variability In Modelling mentioning

confidence: 94%

Generalisability in economic evaluation studies in healthcare: a review and case studies

Sculpher

Fs²,

Manca³

et al. 2004

Health Technol Assess

320

297

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public,...

show abstract

Section: Empirical Analyses Of Geographical Variability In Modelling mentioning

confidence: 94%

Generalisability in economic evaluation studies in healthcare: a review and case studies

Sculpher

Fs²,

Manca³

et al. 2004

Health Technol Assess

320

297

View full text Add to dashboard Cite

show abstract

“…Tanzania was one of the first countries to introduce short‐course therapy, achieving effective cure rates of 86% of patients enrolled in chemotherapy ( Murray et al . 1991 ; De Jonghe et al . 1994 ).…”

Section: Introductionmentioning

confidence: 99%

Costs of tuberculosis for households and health care providers in Dar es Salaam, Tanzania

Wyss

Kilima

Lorenz

2001

Tropical Med Int Health

View full text Add to dashboard Cite

SummaryOBJECTIVE OBJECTIVE To assess the costs of tuberculosis at household level in Dar es Salaam and to compare them with the provider costs of the national tuberculosis control programme. DESIGN D ESIGN Tuberculosis patients were found by active case searching within a routine census in three areas of Dar es Salaam, and by examining records for residents already receiving treatment. Costs at household level were evaluated through a cross-sectional household survey. RESULTS RESULTSOne hundred and ninety-one tuberculosis cases were included in the survey. With treatment periods of 8 to 12 months, extrapolated average costs of a period of illness to patients and their families were as follows: US $2 for examination and laboratory costs, between US $17 and US $50 for consultation and drugs, less than US $1 for hospitalization and between US $13 and US $20 for transport. The analysis revealed high costs due to inability to work, ranging from US $154 to US $1384. These data were compared with the operation costs of the tuberculosis programme and proved to comprise 68% to 94% of total costs. CONCLUSIO NSCONCLUSIONS For patients and their families, tuberculosis implies three main types of cost: drugs, transportation and, most importantly, ®nancial loss due to inability to work. They represent around two thirds of total cost and are a high economic burden for households, in particular those with a lowincome. While assessing tuberculosis control strategies such as direct case ®nding at home, it is therefore important to also include costs incurred at household level.

show abstract

“…treatment for MDR-TB before and after WHO guidelines were adopted (the analysis was undertaken for the same number of patients to avoid distortions caused by different numbers of patients in the cohorts considered before and after the introduction of WHO guidelines). The number of patients following each treatment path, together with their associated costs and effects, was then defined according to: 1) the parameters, parameter distributions and data sources listed in the online supplementary material [29][30][31][32][33][34][35][36][37]; 2) the costs per patient before and after the adoption of WHO guidelines, reported in this article; and 3) treatment outcomes before and after the introduction of treatment according to WHO guidelines, also reported in this article. A Monte Carlo simulation involving 5,000 iterations was used to estimate means and lower and upper bounds (fifth and 95th centiles) for the main outputs of interest, i.e.…”

Section: Treatment Outcomesmentioning

confidence: 99%

Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia

et al. 2012

View full text Add to dashboard Cite

Evidence on the cost and cost-effectiveness of treatment of multidrug-resistant tuberculosis (MDR-TB) is limited, and no published data are available from former Soviet Union countries, where rates of MDR-TB are highest globally.We evaluated the cost and cost-effectiveness of MDR-TB treatment in Estonia and Russia (Tomsk Oblast), comparing cohorts enrolled on treatment according to World Health Organization (WHO) guidelines in 2001 and 2002 with cohorts treated in previous years. Costs were assessed from a health system perspective in 2003 US$; effects were measured as cures, deaths averted and disability-adjusted life-years (DALYs) averted.Cure rates when WHO guidelines were followed were 61% (90 out of 149) in Estonia and 76% (76 out of 100) in Tomsk Oblast, with a cost per patient

show abstract

Cost‐effectiveness of chemotherapy for sputum smear‐positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania

Cited by 19 publications

References 16 publications

Generalisability in economic evaluation studies in healthcare: a review and case studies

Generalisability in economic evaluation studies in healthcare: a review and case studies

Costs of tuberculosis for households and health care providers in Dar es Salaam, Tanzania

Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia

Contact Info

Product

Resources

About